on Piramal Pharma Limited
Piramal Pharma Reports FY2026 Achievements in Annual Report
Piramal Pharma Limited (PPL) has released its FY2026 Annual Report, highlighting its global growth and commitment to innovation and sustainability. The company reported a revenue of ₹8,869 crore, with 66% stemming from regulated markets, underpinning its substantial global presence.
Piramal Pharma Solutions contributed significantly, accounting for 55% of revenues and reinforcing its position within the global CDMO sector. Piramal Critical Care maintained its lead in the US inhaled anesthesia market. Meanwhile, Piramal Consumer Healthcare generated ₹1,274 crore, launching 31 new products and achieving 24% growth in power brands.
The company completed 38 regulatory inspections without receiving any Official Action Indicated (OAI) observations, highlighting its commitment to quality. Sustainability efforts include a 22.6% reduction in greenhouse gas emissions. The company expanded its workforce to over 7,285 employees while ensuring workplace safety with zero fatalities for five consecutive years.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Piramal Pharma Limited news